Paraganglioma: Difference between revisions
Jump to navigation
Jump to search
→Epidemiology: +HLRCC |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 140: | Line 140: | ||
*[[EMA]] -ve. | *[[EMA]] -ve. | ||
**+ve in [[renal cell carcinoma|RCC]]. | **+ve in [[renal cell carcinoma|RCC]]. | ||
*ATRX normal/loss. | |||
**Loss of staining a poor prognosticator in pheochromocytoma/paraganglioma.<ref name=pmid40652840>{{cite journal |authors=Wang LL, Wei XJ, Zhang QC, Li F, Chen GY |title=Analysis of clinicopathological and immunohistochemical features of pheochromocytoma/paraganglioma |journal=Ann Diagn Pathol |volume=79 |issue= |pages=152525 |date=December 2025 |pmid=40652840 |doi=10.1016/j.anndiagpath.2025.152525 |url=}}</ref> | |||
Testing for heritable tumours: | |||
*SDHB (SDHx alterations). | |||
*FH (loss in HLRCC). | |||
*2SC (positive in HLRCC). | |||
*CAIX (+ve in VHL-related). | |||
*Alpha-inhibin (+ve in VHL-related and SHDx alterations). | |||
==EM== | ==EM== | ||